Thus, all current evidence points to the suppression of energy intake being the underlying mechanism responsible for the beneficial effects of GLP-1R agonists on body weight in patients with obesity and/or T2D. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.